Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction
about
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicityMercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.A reliable Raman-spectroscopy-based approach for diagnosis, classification and follow-up of B-cell acute lymphoblastic leukemiaShorter Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia: The Experience of the Prospective, Randomized Brazilian GBTLI ALL-93 Protocol.Meta-analysis of the impact of thioprine S-methyltransferase polymorphisms on the tolerable 6-mercaptopurine dose considering initial dose and ethnic difference.Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?Treatment delay and the risk of relapse in pediatric acute lymphoblastic leukemia.Monitoring and Treatment of Acute Kidney Injury in Children with Acute Lymphoblastic Leukemia After High Dose Methotrexate Chemotherapy.NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia.Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens.Activation of the mitochondrial apoptotic pathway contributes to methotrexate-induced small intestinal injury in rats.NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia.Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia.Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and anti-leukemic efficacy.Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?
P2860
Q28115755-E9A432A4-49DD-46ED-B299-BA07FCE37DD9Q33421300-7F8A73B4-3FCA-4EEF-850F-E72647F4154CQ33441148-4E40CCCF-BE6E-4729-80BB-6C0C835EFED0Q33632120-4153FF0F-23E0-4875-B450-D12459D656D1Q35684384-98994629-F81E-405F-B8F5-2ABBBF9F7CFFQ36810101-7472D97D-115E-4FA4-9ADF-126A4C91E095Q37342837-012EA3A0-5AD2-4764-A3FD-7BECBC2853CDQ37446511-BA26B589-060E-4C2D-856C-C6E39474FFEEQ39570917-DCF8264E-F36E-4288-9F33-C55AF80FC599Q40296977-D94DDA31-B17F-44BB-A749-4F167EF2CC6EQ42110547-0D617E0D-0BDF-4754-8D53-38BCC735CB3AQ43109007-42F64AFB-6C65-4205-90A6-A1FF1A36635FQ45985775-F0AC415D-9263-4081-A21B-1628EE6DCC08Q47856428-7C876E34-AF94-4D23-A863-87973146D9C3Q50115786-C0D70C6F-9E38-455A-81FE-344BE8F03963Q50501063-09EFBD53-582C-4060-A91D-9DF159925279Q51530980-4CF7D0A0-24A6-44B8-8732-FE1765981F26Q51735726-F42D2AE5-8408-4142-9362-0C8B4A688943Q55064299-5CAEAAD1-81D9-4A9C-941B-73E7A1514839
P2860
Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Mercaptopurine/Methotrexate ma ...... ia: clinical facts and fiction
@ast
Mercaptopurine/Methotrexate ma ...... ia: clinical facts and fiction
@en
Mercaptopurine/Methotrexate ma ...... ia: clinical facts and fiction
@nl
type
label
Mercaptopurine/Methotrexate ma ...... ia: clinical facts and fiction
@ast
Mercaptopurine/Methotrexate ma ...... ia: clinical facts and fiction
@en
Mercaptopurine/Methotrexate ma ...... ia: clinical facts and fiction
@nl
prefLabel
Mercaptopurine/Methotrexate ma ...... ia: clinical facts and fiction
@ast
Mercaptopurine/Methotrexate ma ...... ia: clinical facts and fiction
@en
Mercaptopurine/Methotrexate ma ...... ia: clinical facts and fiction
@nl
P2093
P2860
P921
P3181
P1476
Mercaptopurine/Methotrexate ma ...... ia: clinical facts and fiction
@en
P2093
Jacob Nersting
Stine N. Nielsen
Thomas L. Frandsen
P2860
P304
P3181
P356
10.1097/MPH.0000000000000206
P407
P5008
P577
2014-10-01T00:00:00Z